Fig. 4From: 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profilingKEGG pathway hsa05200 “Pathways in cancer”. Genes highlighted in red and green were up-regulated and down-regulated due to the 24h action of bevacizumab/erlotinib, respectivelyBack to article page